News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

FDA Rejects Pfizer Inc. (PFE)'s Drug for Rare Nerve Disease


6/19/2012 6:39:11 AM

Pfizer Inc. (PFE) (PFE), the world’s largest drugmaker, failed to win U.S. regulators’ approval of its drug to treat TTR-FAP, a rare and deadly genetic disorder affecting 8,000 people worldwide. The Food and Drug Administration asked for a second clinical trial showing the effectiveness of tafamidis meglumine, New York-based Pfizer said today in a statement. The pill would be the first approved treatment in the U.S. for TTR-FAP, or Transthyretin Familial Amyloid Polyneuropathy. TTR-FAP robs patients of the use of their limbs from the feet upwards, and as their digestive system turns against them, they waste away and die in about a decade. In Europe, the drug was approved in November for sale under the name Vyndaqel. Pfizer estimates there are 3,000 U.S. patients.

Read at BusinessWeek
Read at Market Watch
Read at Reuters
Read at CBS News


comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES